AB‐Panda: An AI‐Generated Antibody Structure‐Based Tool for Developability Prediction
Biotechnology and Bioengineering · 2026-02 · 123 (2) · 287-297
DOI: 10.1002/bit.70086 ↗At a glance
Journal article in Biotechnology and Bioengineering, 2025-11. Written by Wu Zou and 8 co-authors. Institution: School of Bioscience and Technology, Chengdu Medical College, Chengdu, Sichuan Province, China. Major MEDLINE topics: Antibodies, Artificial Intelligence, Software, Computational Biology. Cited 3 times so far (Crossref); 38 references.
Abstract (original language)
The developability of antibodies is a critical concern in antibody discovery, encompassing issues such as self‐interaction, aggregation, and thermal stability. The use of computational and structure‐based tools has greatly improved the evaluation and prioritization of initial antibody sequences. With the increasing demand for subcutaneous administration of small‐volume, high‐concentration antibody formulations, there is a need for more accurate prediction tools based on protein structures. Our study introduces AB‐Panda, a tool based on AlphaFold2‐predicted antibody structures and three innovative structure‐related metrics. AB‐Panda utilizes unit‐area hydrophobic value (UHV), unit‐area positive charge (UPC), and unit‐area negative charge (UNC) to automatically identify hydrophobic and charged patches within the complementarity determining regions (CDRs) of antibodies. Through the analysis of the 919 clinical stage therapeutic (CST) antibodies, we have established recommended ranges of UHV, UPC, and UNC as reference standards for antibody developability. AB‐Panda offers clear visualizations of surface hydrophobic and charge distribution, facilitating the identification of problematic amino acids and providing suggestions for further sequence engineering. Additionally, AB‐Panda has been integrated into a web application, available at https://www.antibodydev.com , by combining UHV, UPC, UNC, and other established computational metrics for the early screening and optimization of antibody sequences.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- School of Bioscience and Technology, Chengdu Medical College, Chengdu, Sichuan Province, China.
- ABLINK Biotech Co. Ltd, Chengdu, Sichuan Province, China.
- Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, Gansu Province, China.
- Advanced Energy Science and Technology Guangdong Laboratory, Huizhou, Guangdong Province, China.
- Sichuan Higher Education Institute Key Laboratory of Major Disease Target Discovery and Protein Drug Development, Chengdu Medical College, Chengdu, Sichuan Province, China.
ORCID profiles: Wu Zou
Cite
APA
Zou, W., Deng, J., Shen, Y., Zhang, T., Bing, Z., Yuan, L., Huang, C., Liu, J., & Li, X. L. (2026). AB‐Panda: An AI‐Generated Antibody Structure‐Based Tool for Developability Prediction. Biotechnology and Bioengineering, 123(2), 287-297. https://doi.org/10.1002/bit.70086
Vancouver
Zou W, Deng J, Shen Y, Zhang T, Bing Z, Yuan L, et al. AB‐Panda: An AI‐Generated Antibody Structure‐Based Tool for Developability Prediction. Biotechnology and Bioengineering. 2026;123(2):287-297. doi:10.1002/bit.70086
BibTeX
@article{Zou2026,
author = {Zou, Wu and Deng, Jianjun and Shen, Yun and Zhang, Tao and Bing, Zhitong and Yuan, Lingyan and Huang, Chen and Liu, Jianghai and Li, Xin Lei},
title = {AB‐Panda: An AI‐Generated Antibody Structure‐Based Tool for Developability Prediction},
journal = {Biotechnology and Bioengineering},
year = {2026},
volume = {123},
number = {2},
pages = {287--297},
doi = {10.1002/bit.70086}
}
EUVIMED